期刊文献+
共找到1,214篇文章
< 1 2 61 >
每页显示 20 50 100
N-terminal pro-brain natriuretic peptide but not high-sensitivity C-reactive protein is related to severity of coronary artery stenosis in patients with acute coronary syndrome 被引量:1
1
作者 Shi-Jun Li Zhi-Jun Sun +3 位作者 Dan-Dan Li Geng Qian Ting-Shu Yang Xiao-Ying Li 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2010年第2期101-105,共5页
Objective Biochemical indicators such as N-terminal pro-brain type natriuretic peptide(NT pro-BNP)and high-sensitivity Creactive protein(hsCRP)predict mortality in acute coronary syndrome(ACS).However,little is ... Objective Biochemical indicators such as N-terminal pro-brain type natriuretic peptide(NT pro-BNP)and high-sensitivity Creactive protein(hsCRP)predict mortality in acute coronary syndrome(ACS).However,little is known about the relationship of these factors with severity of coronary artery stenosis in patients with.Methods Three hundred and thirty-one subjects including 246 unstable angina pectoris patients and 85 myocardial infarction patients were recruited and classified into two groups:single-vessel disease group(1-vessel disease,n=93)and multiple-vessel disease group(≥2-vessels disease,n=238)according to selective coronary angiography.Plasma levels of NT pro-BNP and hsCRP were measured and severity of coronary stenosis was determined by Gensini score.Results NT pro-BNP but not hsCRP level was higher in patients with myocardial infarction than in patients with unstable angina pectoris.The patients with multiple-vessel disease had significantly higher NT pro-BNP level but not hsCRP compared with those with single-vessel disease.NT pro-BNP levels increased significantly as left ventricle(LV)function decreased,and only NT proBNP but not hsCRP level was related to Gensini score of severity of coronary stenosis in ACS.Conclusion NT proBNP but not hsCRP level is related to severity of coronary artery stenosis in patients in ACS. 展开更多
关键词 N-terminal pro-brain natriuretic peptide high-sensitivity C-reactive protein coronary artery stenosis acute coronary syndrome
在线阅读 下载PDF
Plasma N-terminal pro-brain natriuretic peptide levels in elderly patients with isolated diastolic dysfunction 被引量:2
2
作者 Yixin SONG Qing LIN Xiaomin SHI Yunyun QI 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2005年第4期211-215,共5页
Objective To investigate plasma N-terminal pro-brain natriuretic peptide (NT-BNP) levels and to assess their clinical significance in elderly patients with isolated diastolic dysfunction. Methods Plasma NT-BNP level w... Objective To investigate plasma N-terminal pro-brain natriuretic peptide (NT-BNP) levels and to assess their clinical significance in elderly patients with isolated diastolic dysfunction. Methods Plasma NT-BNP level were measured by electrochemiluminescence immunoassay in 34 symptomatic patients (Group 1), 34 asymptomatic patients (Group 2) with isolated diastolic dysfunction, and in 16 elderly healthy subjects (control group, Group 3), serving controls. Colored Doppler echocardiography was performed to evaluate the patients' cardiac structures and functions. Results The plasma NT-BNP level in Group 1 was significantly higher than those in Group 2 and Group 3 and increased with the severity of heart failure. There was no significant difference of plasma NT-BNP levels between Group 2 and Group 3 (p>0.05). A NT-BNP value of 102.75 pg/mL showed a sensitivity of 88.2%, a specificity of 87.5%, and an accuracy of 88.1% for diagnosing diastolic dysfunction. Patients with restrictive filling pattern on echocardiography had higher NT-BNP levels than those of impaired relaxation pattern (1961.2±304.9 versus 460.1±92.7pg/mL, p<0.001). Conclusion The elevation of plasma NT-BNP level in elderly patients with isolated diastolic dysfunction correlates with the severity of their diastolic abnormalities. The level of plasma NT-BNP has an important clinical value in the diagnosis of elderly patients with isolated diastolic dysfunction. 展开更多
关键词 elderly ISOLATED DIASTOLIC DYSFUNCTION N-TERMINAL pro-brain natriuretic peptide ECHOCARDIOGRAPHY
在线阅读 下载PDF
Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure 被引量:29
3
作者 Qiu-Sheng YIN Bing SHI Lan Dong Lei BI 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2014年第1期79-82,共4页
Background Heart failure (HF) is a common disease with complex pathophysiological causes. The diagnosis of HF commonly relies on comprehensive analyses of medical history and symptoms, and results from echocardiogra... Background Heart failure (HF) is a common disease with complex pathophysiological causes. The diagnosis of HF commonly relies on comprehensive analyses of medical history and symptoms, and results from echocardiography and biochemical tests. Galectin-3, a rela-tively new biomarker in HF, was approved by the US Food and Drug Administration in 2010 as a marker in the stratification of risk for HF. We assessed galectin-3 as a biomarker for HF diagnosis in patients with preserved ejection fraction (pEF) and compared its performance with that of B-type natriuretic peptide (BNP). Methods Thirty-five pEF patients with HF (HFpEF group) and 43 pEF patients without HF (control group) were enrolled. Plasma levels of galectin-3 and BNP in HFpEF and control subjects were determined. Sensitivity, specificity, pre dictive values, and accuracy of galectin-3 and BNP as markers for HF diagnosis were calculated and compared. Results Levels of galec- tin-3 and BNP were 23.09 ±6.97 ng/mL and 270.46 ± 330.41 pg/mL in the HFpEF group, and 16.74 ± 2.75 ng/mL and 59.94 ± 29.93 pg/mL in the control group, respectively. Differences in levels of galectin-3 and BNP between the two groups were significant (P 〈 0.01). As a bio- marker for HF diagnosis in study subjects, galectin-3 showed sensitivity and specificity of 94.3% and 65.1%, respectively, at a cutoff value of 17.8 ug/mL. BNP showed sensitivity and specificity of 77.1% and 90.7%, respectively, at a cutoff value of 100 pg/mL. Galectin-3 was a significantly more sensitive (P 〈 0.05) but less specific (P 〈 0.01) biomarker compared with BNP. Differences in positive predictive value, negative predictive value, and accuracy between galectin-3 and BNP markers were not significant (P 〉 0.05). Areas under the receiver operating characteristic curve (95% confidence interval) were 0.891 (0.808-0.974) and 0.896 (0.809-0.984) for galectin-3 and BNP, respec- tively, with no significant difference between the two values (P 〉 0.05). Conclusions The level of galectin-3 is significantly elevated in patients with HF. Galectin-3 and BNP are useful biomarkers for the diagnosis of HF in patients with pEF. 展开更多
关键词 Heart failure Preserved ejection fraction GALECTIN-3 B-type natriuretic peptide DIAGNOSIS
在线阅读 下载PDF
B-type natriuretic peptide in predicting the severity of community-acquired pneumonia 被引量:19
4
作者 Jing Li Huan Ye Li Zhao 《World Journal of Emergency Medicine》 CAS 2015年第2期131-136,共6页
BACKGROUND: Although pneumonia severity index(PSI) is widely used to evaluate the severity of community-acquired pneumonia(CAP), the calculation of PSI is very complicated. The present study aimed to evaluate the role... BACKGROUND: Although pneumonia severity index(PSI) is widely used to evaluate the severity of community-acquired pneumonia(CAP), the calculation of PSI is very complicated. The present study aimed to evaluate the role of B-type natriuretic peptide(BNP) in predicting the severity of CAP.METHODS: For 202 patients with CAP admitted to the emergency department, BNP levels, cardiac load indexes, inf lammatory indexes including C-reactive protein(CRP), white blood cell count(WBC), and PSI were detected. The correlation between the indexes and PSI was investigated. BNP levels for survivor and non-survivor groups were compared, and a receiver operating characteristic(ROC) curve analysis was performed on the BNP levels versus PSI.RESULTS: The BNP levels increased with CAP severity(r=0.782, P<0.001). The BNP levels of the high-risk group(PSI classes IV and V) were signifi cantly higher than those of the low-risk group(PSI classes I–III)(P<0.001). The BNP levels were signifi cantly higher in the non-survivor group than in the survivor group(P<0.001). In addition, there were positive correlations between BNP levels and PSI scores(r=0.782, P<0.001). The BNP level was highly accurate in predicting the severity of CAP(AUC=0.952). The optimal cut-off point of BNP level for distinguishing high-risk patients from low-risk ones was 125.0 pg/m L, with a sensitivity of 0.891 and a specifi city of 0.946. Moreover, BNP level was accurate in predicting mortality(AUC=0.823). Its optimal cut-off point for predicting death was 299.0 pg/m L, with a sensitivity of 0.675 and a specifi city of 0.816. Its negative predictive cut-off value was 0.926, and the positive predictive cut-off value was 0.426.CONCLUSION: BNP level is positively correlated with the severity of CAP, and may be used as a biomarker for evaluating the severity of CAP. 展开更多
关键词 Community-acquired pneumonia B-type natriuretic peptide Pneumonia severity ndex BIOMARKER EMERGENCY Disease severity assessment
在线阅读 下载PDF
Plasma brain natriuretic peptide level in older outpatients with heart failure is associated with physical frailty, especially with the slowness domain 被引量:5
5
作者 Shu Nishiguchi Yuma Nozaki +4 位作者 Masayuki Yamaji Kanako Oya Yuki Hikita Tomoki Aoyama Hiroshi Mabuchi 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2016年第7期608-614,共7页
Objective To determine the association between plasma brain natriuretic peptide (BNP) level in patients with heart failure (HF) and physical frailty as well as with each domain of physical frailty. Methods Two hun... Objective To determine the association between plasma brain natriuretic peptide (BNP) level in patients with heart failure (HF) and physical frailty as well as with each domain of physical frailty. Methods Two hundred and six outpatients of cardiovascular medicine aged 60 years and older who had been hospitalized for HF or had been given a prescription medication for HF were included. Physical frailty was assessed using the following five domains: slowness, weakness, exhaustion, low activity, and shrinking, according to the Cardiovascular Health Study. Patients were divided into nonfi-ailty and frailty groups according to frailty scores. Plasma BNP level was measured. The 6-min walk test was performed to measure endurance. Results Plasma BNP was significantly different between the two groups (frailty group: 158.0 i 214.7 pg/mL, nonfrailty group: 65.2 ~ 88.0 pg/mL, P 〈 0.01). Multivariate logistic regression analysis revealed log-transformed plasma BNP (Log BNP) was significantly associated with physical frailty (OR: 1.68, 95% CI: 1.11-2.56), and Log BNP was significantly associated with the slowness domain (walking speed 〈 1.0 m/s) of physical frailty (OR: 1.75, 95% Ch 1.15-2.67). Additionally, Log BNP was negatively correlated to the 6-minute walk distance (6MWD) (p=0.37, P 〈 0.01), while 6MWD was positively correlated to walking speed (p = 0.66, P 〈 0.01). Conclusions Plasma BNP level was related to physical frailty, especially in the slowness domain. Endurance may intervene in the associations between plasma BNP level and walking speed. 展开更多
关键词 Brain natriuretic peptide Heart failure Physical frailty Walking speed
在线阅读 下载PDF
Brain natriuretic peptide is a potent vasodilator in aged human microcircula- tion and shows a blunted response in heart failure patients 被引量:5
6
作者 Marie-Louise Edvinsson Erik Uddman Lars Edvinsson Sven E. Andersson 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2014年第1期50-56,共7页
Background Brain natriuretic peptide (BNP) is normally present in low levels in the circulation, but it is elevated in parallel with the degree of congestion in heart failure subjects (CHF). BNP has natriuretic ef... Background Brain natriuretic peptide (BNP) is normally present in low levels in the circulation, but it is elevated in parallel with the degree of congestion in heart failure subjects (CHF). BNP has natriuretic effects and is a potent vasodilator. It is suggested that BNP could be a therapeutic alternative in CHF. However, we postulated that the high levels of circulating BNP in CHF may downregulate the response of microvascular natriuretic receptors. This was tested by comparing 15 CHF patients (BNP 〉 3000 ng/L) with 10 matched, healthy controls. Methods Cutaneous microvascular blood flow in the forearm was measured by laser Doppler Flowmetry. Local heating (+44°C, 10 min) was used to evoke a maximum local dilator response. Results Non-invasive iontophoretic administration of either BNP or acetylcholine (ACh), a known endothelium-dependent dilator, elicited an increase in local flow. The nitric oxide synthase inhibitor, l-N-Arginine- methyl-ester (L-NAME), blocked the BNP response (in controls). Interestingly, responses to BNP in CHF patients were reduced to about one third of those seen in healthy controls (increase in flow: 251% in CHF vs. 908% in controls; P 〈 0.001). In contrast, the vasodilator responses to ACh and to local heating were only somewhat attenuated in CHF patients. Thus, dilator capacity and nitric oxide signalling were not af- fected to the same extent as BNP-mediated dilation, indicating a specific downregulation of the latter response. Conclusions The findings show for the first time that microvascular responses to BNP are markedly reduced in CHF patients. This is consistent with the hypothesis of BNP receptor function is downregulated in CHF. 展开更多
关键词 Heart failure Cutaneous microcirculation Endothelial responses Acetylcholine Brain natriuretic peptide Nitric oxide
在线阅读 下载PDF
CHANGES OF PLASMA ENDOTHELIN AND ATRIAL NATRIURETIC PEPTIDE DURING THE ONSET AND AFTER TERMINATION OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA 被引量:1
7
作者 李春盛 田茹敏 +3 位作者 朱丽楠 李丹宇 冯启刚 高秀兰 《Chinese Medical Sciences Journal》 CAS CSCD 1995年第3期161-164,共4页
Radioimmunoassays were used to measure the concentration changes of plasma endothelin(ET) and atrial natriuretic peptide(ANP) during the onset and after termination of paroxysmal supraventricular tachycardia(SVT). 30 ... Radioimmunoassays were used to measure the concentration changes of plasma endothelin(ET) and atrial natriuretic peptide(ANP) during the onset and after termination of paroxysmal supraventricular tachycardia(SVT). 30 cases were reviewed and compansons with 42 normal subjects were made. There are very significant differences(P<0.0001) in the concentration changes of both plasma ET and ANP during the onset and 30 minutes after the termination of SVT. During the onset period of SVT. the plasma ET and ANP were markedly elevated and 30 minutes after its termination they were lowered significantly, but their concentrations were still 2-fold higher than ihose of the control group. As the biological effects of ANP and ET are antagonistic to each other. their parallel elevation and lowering of plasma concentrations during and.after the termination of SVT reveal that these 2 hormones parucipate in the pathophysiological process of SVT. This phenomenon is possibly one of the homeostatic regulatory functions in the organism. 展开更多
关键词 paroxysmal supraventricular tachycardia ENDOTHELIN atrial natriuretic peptide
在线阅读 下载PDF
Serum brain natriuretic peptide in children with Kawasaki disease 被引量:1
8
作者 Yu-ping Sun Chao-ping Wei +4 位作者 Wen-di Wang Xing-chang Zheng Ye-jun Wang Shao-chun Ma Ying-jun Xu 《World Journal of Emergency Medicine》 SCIE CAS 2010年第2期114-117,共4页
BACKGROUND: Kawasaki disease (KD) is a common cause of acquired heart disease in children. Recent studies have focused on the biochemical markers of the myocardium, their high sensitivity and specificity and signif... BACKGROUND: Kawasaki disease (KD) is a common cause of acquired heart disease in children. Recent studies have focused on the biochemical markers of the myocardium, their high sensitivity and specificity and significance in the diagnosis of KD. This study aimed to determine the serum level of brain natriuretic peptide (BNP) and its relation with the heart function of children with KD and to explore its clinical value in diagnosis of KD.METHODS: Forty-three KD children, aged from 5 months to 8 years (mean 2.3±0.6 years ), were admitted to Qingdao Children's Hospital from February 2007 to April 2009. Among them 27 were male, and 16 female. The 43 patients served as a KD group. Patients with myocarditis, cardiomyopathy, congenital heart disease and other primary heart diseases were excluded. Thirty healthy children, aged from 3 months to 15 years (mean 2.5±0.8 years) or 17 males and 13 females served as a control group. There were no significant differences in age and gender between the two groups (P〉0.05). In the KD group, ELISAwas used to measure the levels of serum BNP in acute and convalescent stages; and in the control group, the levels of serum BNP were measured once randomly. Left ventricular ejection fraction (LVEF), left ventricular shorten fraction (LVSF), cardiac index (CI) and left ventricular inflow velocity through the mitral annulus (including E-velocity and A-velocity) were measured by two- dimensional echocardiography in the acute and convalescent stages in the KD group. All data were expressed as mean±SD. The methods of analysis included Student's t test and the linear regression analysis test. P〈0.05 was considered statistically significant.RESULTS: The level of serum BNP in the acute stage (517.26±213.40) ng/ml was significantly higher than that in the convalescent stage (91.56±47.97) ng/ml in the control group (37.55±7.56) ng/ ml (P〈0.01). The levels of LVEF, LVSF and CI in the acute stage were significantly lower than those in the convalescent stage (P〈0.05), but the E/A level was not significantly different between the acute and convalescent stages (P〉0.05). Linear regression analysis showed that the BNP level was negatively correlated with the levels of LVEF, LVSF and C1(r=-0.63, -0.52, -0.53, P〈0.05) , but not significantly correlated with the E/A level (r=-0.18, P〉0.05).CONCLUSION: The levels of serum BNP are significantly increased in KD patients, and are negatively correlated with the levels of LVEF, LVSF, and CI. The detection of serum BNP level is of clinical significance in the diagnosis of KD. 展开更多
关键词 natriuretic peptide BRAIN Kawasaki disease Ejection fraction left ventricular Shorten fraction left ventricular Cardiac index E/A CORRELATION CHILDREN
在线阅读 下载PDF
Relationship between contents of plasma atrial natriuretic peptide and serum lipids of atherosclerosis in rabbits
9
作者 卞金陵 方超平 +3 位作者 周勇 承建国 李闻杰 蔡东联 《Journal of Medical Colleges of PLA(China)》 CAS 1993年第4期381-384,共4页
Changes in plasma atrial natriuretic peptide(ANP)and serum lipids were observed us-ing dietetic atherosclerosis(AS)models.The results showed that plasma ANP level of the ASgroup was significantly higher than that of t... Changes in plasma atrial natriuretic peptide(ANP)and serum lipids were observed us-ing dietetic atherosclerosis(AS)models.The results showed that plasma ANP level of the ASgroup was significantly higher than that of the control group(14.33±3.58μg/L vs 9.43±3.14μg/L).There was also a marked increase in serum Tch,TG,LDL-ch and VLDL-ch comparedwith the control group(P【0.01),suggesting that release of ANP increased with disturbance ofthe serum lipids and during AS formation,and that change in ANP was closely related to Tchand LDL-ch(P【0.05).Possible mechanisms causing these changes are also discussed. 展开更多
关键词 ATRIAL natriuretic peptide ATHEROSCLEROSIS serum LIPIDS RABBITS
在线阅读 下载PDF
Effects of highly potent atrial natriuretic peptide on circulating reninangiotensin-aldosterone system and cardiac function in dogs with ischemic heart failure
10
作者 吴宏超 钱学贤 +3 位作者 冯常森 王佳勇 张勇 施傅涛 《Journal of Medical Colleges of PLA(China)》 CAS 1997年第2期136-139,共4页
The effects of highly-potent atrial natriuretic peptide (HPANP) on circulating re nin-angiotensin-aldos-terone system (RAAS) and cardiac function were studied in an acute ischemic heart failure model. HPANP (6 μg/kg ... The effects of highly-potent atrial natriuretic peptide (HPANP) on circulating re nin-angiotensin-aldos-terone system (RAAS) and cardiac function were studied in an acute ischemic heart failure model. HPANP (6 μg/kg and 3 μg/kg) was infused intracoronarily. It was found that both doses of HPANP could cause significant decrease in plasma renin activity (PRA), angiotensin II (AII) and aldosterone (Ald). After the administraticn of HPANP, PRA, AII and Ald in the coronary sinus were decreased by 73. 2% (P<0.01), 68. o% (P<0.01) and 73. 6% (P<0.01), and the hormones in peripheral venous blood by 63. 3% (P<0.01), 53. 3% (P<0.01) and 64. 9% (P<0.01), respectively at the dose of 6 μg/kg. While PRA, AII and Ald in the coronary sinus and in peripheral venous blood decreased by 55. 9%, 55. 3%, 61. 9%, and 54. 0%, 42. 3%, 53, 3%, respectively at the 3μg/kg dose level. At the higher dose, HPANP increased left ventricular systolic pressure (LVSP, +13. 1%, P<0. 05), +dP/dtmax(+24.1 %, P<0.01), -dp/dtmax (+35.9%, P<0.01), and VCE(+28.9%, P<0.05). Mean arterial pressure and left ventricular end-diastolic pressure (LVEDP) were decreased (-15.0%, P<0.01, and 29. 6%, P<0.01, respectively). In contrast, the lower dose caused no significant changes of LVSP, +dp/dtmex,dp/dtmax and VCE(not including LVEDP, - 20. 5 %, P<0.05). Neither of the doses caused significant changes in heart rate and T value- Normal saline infusion has no effects on cardiac function and circulating RAAS- We conclude that in ischemic heart failure, intracoronary administration of HPANP can significantly suppress the activity of circulating RAAS, and improve cardiac function by reducing pre- and after-load of the heart, but has no direct myocardial effects. 展开更多
关键词 highly POTENT ATRIAL natriuretic peptide renin-angiotensin-aldosterone system myocardial ischemia heart failure
在线阅读 下载PDF
Plasma brain natriuretic peptide and atria natriuretic peptide as predictors for diastolic heart failure in patients with type 2 diabetes mellitus
11
作者 Yi-Tian Chen Ting-Song Liu +2 位作者 Shi-Sen Jiang Rui-Ji Xu Cheng Huang 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2009年第4期227-229,共3页
Objective To study the change of diastolic cardiac function in diabetic patients and to determine the diagnostic value of plasma brain natriuretic peptide (BNP) and atria natriuretic peptide (ANP) for diastolic he... Objective To study the change of diastolic cardiac function in diabetic patients and to determine the diagnostic value of plasma brain natriuretic peptide (BNP) and atria natriuretic peptide (ANP) for diastolic heart failure in patients with type 2 diabetes mellitus. Methods Twelve healthy subjects and seventy-one diabetic patients were included in the study. Plasma BNP and ANP were measured with immtmoradiometic assay. Results Plasma levels of BNP and ANP increased significantly with increased severity of diastolic heart dysfunction. The ratio of E/A had significant negative correlation with the plasma levels ofBNP (r=0.669,P〈0.001) and ANP (r=0.579, P〈0.01). AUC of ANP and BNP in ROC model was 91.9% and 65.3%, respectively. Conclusions The plasma level of BNP might be a valuable predictor for differential diagnosis of diastolic cardiac function in diabetic patients. 展开更多
关键词 diabetes mellitus brain natriuretic peptide atria natriuretic peptide diastolic heart failure
在线阅读 下载PDF
C-TYPE NATRIURETIC PEPTIDE INHIBITS UPREGULATION OF α1-ADRENOCEPTOR AND INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR IN RAT VASCULAR SMOOTH MUSCLE AFTER VASCULAR ENDOTHELIAL INJURY
12
作者 王晓红 杨军 +3 位作者 佟利家 苏静怡 唐朝枢 刘乃奎 《Chinese Medical Sciences Journal》 CAS CSCD 2000年第2期73-78,共6页
Objective.In a model of balloon injury of rat aortic endothelium, the effects of C-type natriuretic peptide(CNP) on α 1-adrenoreceptor and inositol 1,4,5-triphosphate (IP 3) receptor were st... Objective.In a model of balloon injury of rat aortic endothelium, the effects of C-type natriuretic peptide(CNP) on α 1-adrenoreceptor and inositol 1,4,5-triphosphate (IP 3) receptor were studied Methods. Aortic injuries were produced by vascular endothelium-denudation.α 1- adrenoreceptor in smooth muscle sarcolemma and IP 3 receptor in smooth muscle sarcoplasmic reticulum in the rat aorta were assayed by radioactive analysis method Results. It was found that neointima was formed and the contents of DNA, collagen and elastin of each intimamedia were significantly increased in 7 days and 21 days after balloon injury of rat aorta. α 1adrenoreceptor in smooth muscle sarcolemma and IP 3 receptor in sarcoplasmic reticulum were also upregulated. Results also showed that the administration of CNP ip significantly decreased the contents of DNA, collagen and elastin of each intimamedia, and inhibited the upregulation of α 1adrenoreceptor and IP 3 receptor Conclusion. The inhibition of the upregulation of α 1adrenoreceptor and IP 3 receptor by CNP might be one of the mechanisms of its suppressive action on intimal proliferation 展开更多
关键词 restenosis balloon angioplasty C-type natriuretic peptide
在线阅读 下载PDF
The role of B-type natriuretic peptide in the diagnosis and treatment of decompensated heart failure
13
作者 MichaelJ.Gallagher PeterA.McCullough 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2004年第1期21-28,共8页
Heart failure (HF) is a common disease associated with increasing age. B-type natriuretic peptide (BNP), is a cardiac neurohormone, and is released as prepro BNP and then enzyrnatically cleaved to the Ntenninal-proBNP... Heart failure (HF) is a common disease associated with increasing age. B-type natriuretic peptide (BNP), is a cardiac neurohormone, and is released as prepro BNP and then enzyrnatically cleaved to the Ntenninal-proBNP (NT-proBNP) and BNP upon ventricular myocyte stretch. Blood measurements of BNP have been used to identify patients with I-IF. The BNP assay is currently used as a diagnostic and prognostic aid in HF. In general, a BNP level below 100 pg/mL excludes acutely decompensated HF and levels > 500 pg/ml indicate decompensation. Recombinant human BNP (hBNP, nesiritide) is an approved intravenous treatment for acute,decompensated -HF. Nesiritide given in supraphysiologic doses causes vasodilation, natriuresis, diuresis, and improved symptoms over the course of a 48-hour infusion. This paper will sort out the literature concerning the use of this peptide both as a diagnostic test and as an intravenous therapy. 展开更多
关键词 BNP The role of B-type natriuretic peptide in the diagnosis and treatment of decompensated heart failure TYPE
在线阅读 下载PDF
Understanding heart failure in the elderly with respect to diastolic dysfunction and role for natriuretic peptides
14
作者 Thomas G.Allison 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2005年第4期216-217,共2页
The current issue of the Journal of Geriatric Cardiology contains an interesting paper by Dr. Yixin Song and colleagues raising important issues in the diagnosis and management of heart failure in elderly patients. Re... The current issue of the Journal of Geriatric Cardiology contains an interesting paper by Dr. Yixin Song and colleagues raising important issues in the diagnosis and management of heart failure in elderly patients. Readers of this journal are in all likelihood aware that the epidemic of heart failure is of great impact medically and economically worldwide. 展开更多
关键词 BNP Understanding heart failure in the elderly with respect to diastolic dysfunction and role for natriuretic peptides
在线阅读 下载PDF
N‑terminal pro‑brain natriuretic peptide–a significant biomarker of disease development and adverse prognosis in patients with exertional heat stroke
15
作者 Long Feng Jian-Yuan Yin +5 位作者 Yao-Hong Liu Pei Zhang Ya-Li Zhao Qing Song Ping Ping Shi-Hui Fu 《Military Medical Research》 2025年第3期461-463,共3页
Dear Editor,The most serious heat related injury is exertional heat stroke(EHS).EHS occurs when healthy individuals perform physical activity in a hot and humid environment[1].A disrupted balance between heat producti... Dear Editor,The most serious heat related injury is exertional heat stroke(EHS).EHS occurs when healthy individuals perform physical activity in a hot and humid environment[1].A disrupted balance between heat production and dissipation in the human body results in excessive body heat storage in cases.It occurs frequently in the military population because of work characteristics such as the requirements to perform essential duties under prolonged heat stress,the need to achieve mission objectives during deployment operations,or the opportunities for training and selection for elite units[2].The pathophysiology of EHS is complex,which often results in thermoregulation failure,hemodynamic disturbance,and endotoxin release,and further causes multiple organ failure,probably increasing myocardial enzymes and N-terminal pro-brain natriuretic peptide(NT-proBNP)levels.Rhabdomyolysis caused by EHS often results from mechanical and metabolic injury to the striated muscle fibers accompanied with the release of muscle contents into the circulation[3].Liu et al. 展开更多
关键词 Exertional heat stroke Mortality Myocardial enzymes N-terminal pro-brain natriuretic peptide(NTproBNP) Physical activity
在线阅读 下载PDF
小豆利钠肽VaEG45的原核表达纯化和生物活性分析
16
作者 王慧鑫 孙伟娜 +1 位作者 柯希望 左豫虎 《黑龙江八一农垦大学学报》 2025年第1期8-14,87,共8页
为获得小豆利钠肽VaEG45纯化蛋白并明确其生物活性,利用pET-30a(+)构建VaEG45原核表达载体,大肠杆菌原核表达系统表达VaEG45蛋白,Ni-NTA层析柱纯化VaEG45蛋白,并用纯化蛋白处理小豆原生质体检测其活性。结果表明:构建的p ET-30a-His-VaE... 为获得小豆利钠肽VaEG45纯化蛋白并明确其生物活性,利用pET-30a(+)构建VaEG45原核表达载体,大肠杆菌原核表达系统表达VaEG45蛋白,Ni-NTA层析柱纯化VaEG45蛋白,并用纯化蛋白处理小豆原生质体检测其活性。结果表明:构建的p ET-30a-His-VaEG45重组载体可使His-VaEG45蛋白在大肠杆菌中正确高效表达,表达蛋白分子量为11.6 kDa,纯化后蛋白浓度为0.49 mg·mL^(-1),纯度为90%;生物活性分析发现,His-VaEG45纯化蛋白可刺激小豆原生质体细胞膨大。研究成功表达并纯化了具有生物活性的His-VaEG45蛋白,为深入解析VaEG45蛋白参与小豆抗锈病的生理和分子机制提供基础。 展开更多
关键词 小豆 植物利钠肽 蛋白表达 生物活性
在线阅读 下载PDF
液质联用法测定重组人脑利钠肽的质量肽图
17
作者 张竞 安进城 +3 位作者 李丹丹 周志艳 任新桐 邹卫 《中国医药科学》 2025年第5期17-20,66,共5页
目的建立重组人脑利钠肽(rhBNP)的肽图分析方法,同时绘制其质量肽图并鉴定二硫键位点。方法摸索合适的酶切条件,用液质联用的方法绘制质量肽图和定位二硫键,并进行重复性、精密度和耐用性相关验证。结果rhBNP经还原及烷基化后进行酶切,... 目的建立重组人脑利钠肽(rhBNP)的肽图分析方法,同时绘制其质量肽图并鉴定二硫键位点。方法摸索合适的酶切条件,用液质联用的方法绘制质量肽图和定位二硫键,并进行重复性、精密度和耐用性相关验证。结果rhBNP经还原及烷基化后进行酶切,胰蛋白酶与蛋白质量比为1∶100时,可以得到稳定的肽图谱。通过分析理论结果,确认二硫键位置。方法学验证结果表明,该方法重复性、精密度及耐用性良好。对连续3批生产的中试产品进行肽图分析,供试品与对照品的肽图谱完全一致。结论本研究建立的肽图分析方法可应用于rhBNP的鉴别和质量控制。 展开更多
关键词 液质联用 肽图 重组人脑利钠肽 心力衰竭
在线阅读 下载PDF
注射用重组人脑利钠肽不良反应的文献计量学分析
18
作者 王建博 赵振宇 《天津药学》 2025年第1期116-119,124,共5页
目的分析注射用重组人脑利钠肽药物不良反应(ARD)的发生、分布、严重程度及有效防治措施,为促进临床合理使用注射用重组人脑利钠肽提供可行性用药参考。方法检索中国知网(CNKI)、中国生物医学文献服务系统(SinoMed)、维普、PubMed、Web ... 目的分析注射用重组人脑利钠肽药物不良反应(ARD)的发生、分布、严重程度及有效防治措施,为促进临床合理使用注射用重组人脑利钠肽提供可行性用药参考。方法检索中国知网(CNKI)、中国生物医学文献服务系统(SinoMed)、维普、PubMed、Web of Science数据库关于注射用重组人脑利钠肽ADR的文献,截止到2024年6月30日。使用Excel软件对发文量以及注射用重组人脑利钠肽ARD的病例数量、ADR类型和防治措施进行计量学分析。结果本文共纳入统计文献125篇,病例6046例,其中明确发生与注射用重组人脑利钠肽使用相关的ADR 628例,总ADR发生率为10.39%(628/6046)。ADR类型包括低血压、低钠血症、头晕头疼等。结论注射用重组人脑利钠肽在常规剂量下临床使用疗效好,ADR发生率较低,安全性高,但对于可能发生的ADR仍需给予足够的重视。注射用重组人脑利钠肽采用维持量连续给药方式或降低维持给药剂量,疗效与常规剂量相当,还可降低ADR发生率,值得临床医生借鉴。 展开更多
关键词 注射用重组人脑利钠肽 不良反应 文献计量学分析
在线阅读 下载PDF
沙库巴曲缬沙坦钠与重组人脑利钠肽序贯用药方案治疗慢性心力衰竭的效果
19
作者 朱艳卫 王勇 《罕少疾病杂志》 2025年第3期89-91,共3页
目的 探讨沙库巴曲缬沙坦钠与重组人脑利钠肽序贯用药方案治疗慢性心力衰竭(CHF)的效果。方法 取2022年12月至2023年12月期间,本院收治的110例CHF患者,随机数字表法分组,对照组55例采取常规治疗加重组人脑利钠肽,观察组55例采取常规治... 目的 探讨沙库巴曲缬沙坦钠与重组人脑利钠肽序贯用药方案治疗慢性心力衰竭(CHF)的效果。方法 取2022年12月至2023年12月期间,本院收治的110例CHF患者,随机数字表法分组,对照组55例采取常规治疗加重组人脑利钠肽,观察组55例采取常规治疗加沙库巴曲缬沙坦钠与重组人脑利钠肽序贯用药方案,对两组治疗效果进行比较。结果 与对照组总有效率比较,观察组明显更高(P<0.05);对照组治疗后比较,观察组NT-pro BNP、IVSS、LVMI、LVPET、MEE、c ESS更低,LVEF、SV、LVFS更高(P<0.05)。结论 沙库巴曲缬沙坦钠与重组人脑利钠肽序贯用药方案用于CHF治疗中效果满意,可改善心功能与心肌能量代谢状态,调节心室重构。 展开更多
关键词 沙库巴曲缬沙坦钠 重组人脑利钠肽 慢性心力衰竭 心室重构
在线阅读 下载PDF
冻干重组人脑利钠肽联合呋塞米治疗急性心力衰竭伴肾功能不全的临床效果
20
作者 何晓胜 沈佳佳 +2 位作者 王顺利 许振 刘淼 《天津药学》 2025年第3期274-277,281,共5页
目的探讨冻干重组人脑利钠肽联合呋塞米治疗急性心力衰竭伴肾功能不全的临床效果。方法选取2020年3月至2023年7月濮阳市人民医院收治的96例急性心力衰竭伴肾功能不全患者,按照随机数字表法分为实验组和对照组,各48例。对照组予以呋塞米... 目的探讨冻干重组人脑利钠肽联合呋塞米治疗急性心力衰竭伴肾功能不全的临床效果。方法选取2020年3月至2023年7月濮阳市人民医院收治的96例急性心力衰竭伴肾功能不全患者,按照随机数字表法分为实验组和对照组,各48例。对照组予以呋塞米,实验组予以呋塞米联合冻干重组人脑利钠肽。对比两组疗效、肾功能[尿素氮(BUN)、肌酐(CREA)]、尿量、血钾、血钠、心功能[6 min步行距离(6MWD)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)]、神经内分泌因子[血管紧张素Ⅱ(AngⅡ)、内皮素(ET)、心房钠尿肽(ANP)]水平、不良反应。结果实验组总有效率[91.67%(44/48)]较对照组[75.00%(36/48)]高(P<0.05);治疗后,实验组BUN[(10.35±4.67)mmol/L]、CREA[(126.47±95.35)μmol/L]水平较对照组[(13.97±6.04)mmol/L、(175.35±124.02)μmol/L]低(P<0.05);治疗后,实验组尿量[(2103.01±125.36)mL]、血钾[(4.25±0.61)mmol/L]、血钠[(149.26±9.05)mmol/L]较对照组[(1359.24±87.98)mL、(3.28±0.53)mmol/L、(135.71±8.67)mmol/L]高(P<0.05);治疗后,实验组6MWD[(382.45±60.02)m]较对照组[(327.25±57.35)m]远,LVEDD[(21.56±9.18)mm]、LVESD[(35.34±6.04)mm]水平较对照组[(27.37±9.86)mm、(41.39±7.35)mm]低(P<0.05);治疗后,实验组AngⅡ[(100.35±7.25)ng/mL]、ET[(48.62±3.17)ng/L]、ANP[(243.54±12.49)ng/L]水平较对照组[(117.53±8.47)ng/mL、(61.48±3.53)ng/L、(314.73±14.25)ng/L]低(P<0.05);两组不良反应发生率对比无显著差异(P>0.05)。结论呋塞米联合冻干重组人脑利钠肽治疗急性心力衰竭伴肾功能不全患者效果确切,可改善肾功能,促进心功能恢复,调节神经内分泌因子指标,且安全性较佳。 展开更多
关键词 急性心力衰竭 呋塞米 冻干重组人脑利钠肽 肾功能不全
在线阅读 下载PDF
上一页 1 2 61 下一页 到第
使用帮助 返回顶部